Across our campus and throughout our nearly 400 years, Harvard innovation—in medicine, technology, education, and beyond—has ...

Psychiatric medication is controversial. While most recognise that mental health problems are caused by a tangle of psychological, social and biological factors, debates about solutions are polarised ...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), have ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

The Europe Pharmaceutical Drugs Market size is valued at USD 450 billion in 2025 and is expected to reach USD 610 billion by ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

Glenmark Pharmaceuticals has signed a groundbreaking deal with AbbVie to commercialize its underdevelopment drug, ISB 2001, ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...